| Understanding GLP-1 analogs and enhancing patients success. | |
| | |
MedLine Citation:
|
PMID: 20736387 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recent research into the mechanisms of type 2 diabetes reveals intricate interactions among many hormonal processes. Ultimately, these pathways lead to hyperglycemia, pancreatic beta-cell failure, and the emergence of type 2 diabetes. The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are now known to play major roles in endogenous glucose control, including regulation of insulin, glucagon, and hepatic glucose metabolism. Investigation of the incretin system has led to development of drugs that mimic or enhance the endogenous hormones, including GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. This supplement describes the role of incretin hormones in the pathophysiology of type 2 diabetes and their potential as therapeutic targets for disease management. In addition, safety and efficacy profiles of the GLP-1 receptor agonists are reviewed, and the advantages and limitations of these medications are discussed from the perspective of promoting their successful implementation in individualized treatment regimens. As understanding of the underlying pathophysiology and pathogenesis of type 2 diabetes advances, the number of new therapeutic approaches expands. GLP-1 receptor agonists address several aspects of the pathophysiology of type 2 diabetes. A large body of data reveals the efficacy, safety, and tolerability of these drugs. A clear understanding of the evidence base for these drugs will translate into improved education of patients regarding their options to improve glycemic control and, ultimately, to better patient care. |
| | |
Authors:
|
Davida F Kruger; Bruce Bode; Geralyn R Spollett |
Related Documents
:
|
15691867 - Role of nitric oxide mechanisms in gastric emptying of, and the blood pressure and glyc... 12216497 - Enhancement of insulin secretory response to glucose-dependent insulinotropic polypepti... 9928027 - On the treatment of diabetes mellitus with glucagon-like peptide-1. 18087847 - Dipeptidyl peptidase-iv inhibitors: fixing type 2 diabetes? 9069587 - Increased complications in noninsulin-dependent diabetic patients treated with insulin ... 164437 - Effects of adenosine deaminase on cyclic adenosine monophosphate accumulation, lipolysi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Diabetes educator Volume: 36 Suppl 3 ISSN: 1554-6063 ISO Abbreviation: Diabetes Educ Publication Date: 2010 Jul-Aug |
Date Detail:
|
Created Date: 2010-08-25 Completed Date: 2011-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7701401 Medline TA: Diabetes Educ Country: United States |
Other Details:
|
Languages: eng Pagination: 44S-72S; quiz 73S-74S Citation Subset: N |
Affiliation:
|
Division of Endocrinology, Diabetes, Bone and Mineral Disorders, Henry Ford Health System, Detroit, Michigan 48202, USA. Dkruger1@HFHS.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Glucose
/
metabolism Diabetes Mellitus, Type 2 / drug therapy, etiology, metabolism, physiopathology* Glucagon-Like Peptide 1 / physiology*, therapeutic use Humans Incretins / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Incretins; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physical activity preferences and type 2 diabetes: exploring demographic, cognitive, and behavioral ...
Next Document: Self-reported and laboratory-based responses to stress in children with recurrent pain and anxiety.